Sophiris Bio (SPHS) Stock Price, News & Analysis

Company Overview

Sophiris Bio Inc. was a biotechnology company focused on developing therapies for urological diseases and cancers. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio as it concentrated on treatments designed to selectively target diseased tissue.

Sophiris Bio’s primary investigational product was topsalysin, also known as PRX302. The product was a recombinant protein engineered to become activated by prostate-specific antigen, an enzyme found at elevated levels in prostate tissue. The company studied topsalysin as a potential treatment for benign prostatic hyperplasia, a noncancerous enlargement of the prostate, as well as for prostate cancer.

Sophiris Bio conducted clinical development activities in North America and sought to advance its products through partnerships and additional development agreements. The company’s programs remained investigational and were not established as approved commercial products. Publicly available information about its later operations and leadership is limited.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $4 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 5/09/2019
• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:SPHS
• CIK: 1563855
• Web: www.sophirisbio.com
• Phone: (858) 777-1760
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,550,000
• Free Float: N/A
• Market Cap: $4 thousand
• Optionable: Not Optionable
• Beta: 1.94